FIGURE 3.

(a) Flowchart of clinical studies; (b) FGF21 relative expression in liver biopsies from healthy controls, simple steatosis and MASH patients classified according to SAF Score; (c) Transcriptomic analysis of FGF21 mRNA expression in healthy controls, bland steatosis and steatohepatitis revealed that FGF21 expression correlated with liver damage progression. Data are expressed as mean $\pm$ SEM. FGF21, Fibroblast Growth Factor 21; MASH, metabolic dysfunction associated steatohepatitis; SS, Simple Steatosis. *p $\le$ 0.05; ***p < 0.001.